05:29 AM EDT, 08/21/2025 (MT Newswires) -- Alvotech ( ALVO ) and UK-based Advanz Pharma said Thursday that their Mynzepli fusion protein was approved by the European Commission to treat retinal diseases, including neovascular age-related macular degeneration.

The companies said the approval was based on non-clinical and clinical similarity data, which included a confirmatory efficacy study comparing Mynzepli with Bayer's Eylea in patients with neovascular age-related macular degeneration.

Mynzepli will be available in European Economic Area countries as a 40 mg/mL solution for injection in a pre-filled syringe or a vial, the companies said.

Shares of Alvotech ( ALVO ) rose more than 1% in recent Thursday premarket activity.